A single-arm phase II trial of palbociclib in combination with tamoxifen as first-line therapy for metastatic hormone receptor-positive breast cancer.

Authors

Oana Cristina Danciu

University of Illinois at Chicago, Chicago, IL

Oana Cristina Danciu , Kent Hoskins , Cristina I. Truica , Anne Hudson Blaes , Deimante Tamkus , Jatin Rana , Pavankumar Tandra , Lauren Green , Menggang Yu , Qianqian Zhao , Deborah Toppmeyer , Ruth O'Regan , Kari Braun Wisinski

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Clinical Trial Registration Number

02668666

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 1056)

DOI

10.1200/JCO.2021.39.15_suppl.1056

Abstract #

1056

Poster Bd #

Online Only

Abstract Disclosures

FEATURED

A single-arm phase II trial of palbociclib in combination with tamoxifen as first-line therapy for metastatic hormone receptor-positive breast cancer.

Authors

Oana Cristina Danciu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Clinical Trial Registration Number

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies.

Poster

Lasofoxifene as a potential treatment for ER+ metastatic breast cancer.

Poster

Impact of metastases directed radiation therapy on CDK4/6 inhibitors dose reduction and treatment discontinuation for metastatic HR+/HER2- breast cancer (MBC).

Poster

Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC).